Modernizing Pharma Governance: India to Launch Unified Digital Platform for Drug Regulation Within 18 Months

NEW DELHI — In a major effort to streamline pharmaceutical governance, India’s Central Drugs Standard Control Organisation (CDSCO) has announced plans to roll out a fully integrated digital drug regulatory framework over the next 18 months. The initiative, named the Digital Drugs Regulatory System (DDRS), seeks to replace a series of fragmented web portals with a single-window interface. The goal is to accelerate approval timelines, strengthen transparency, and elevate global competitiveness for India’s $50 billion pharmaceutical industry.

A Unified Architecture to Replace Fragmented Portals

For years, pharmaceutical firms and medical device manufacturers in India have had to navigate a patchwork of disparate regulatory portals. These include:

• SUGAM: Managed import approvals and clinical trials.

• MD Online: Handled medical device registrations.

• ONDLS: Managed state-level licensing and export documentation.

• SUGAM LABS: Handled testing workflows.

Industry stakeholders have noted that this fragmented setup required redundant data entry, caused inconsistent document submissions, and offered limited real-time tracking. Frequent technical downtimes across these isolated portals also contributed to delays in critical regulatory decisions.

       LEGACY SYSTEM                            PROPOSED DDRS PLATFORM
+---------------------------+                +---------------------------+
| SUGAM  (Imports/Trials)   |                |                           |
| MD Online (Devices)       |  == Merge ==>  |   Unified API-First DPI   |
| ONDLS  (State Licenses)   |   Into One     |     Single-Window Portal  |
| SUGAM LABS (Testing)      |                |                           |
+---------------------------+                +---------------------------+
                                                           |
                                             +-------------+-------------+
                                             |                           |
                                      [Connected To]              [Connected To]
                                      GST & Customs                 ICMR & States

The new DDRS is designed to consolidate these separate functions into an API-first platform built on Digital Public Infrastructure (DPI) principles. The system will cover drugs, biologicals, medical devices, cosmetics, veterinary products, and novel therapies regulated by both central and state authorities. Under this model, a company submits its data once, which then flows securely to interconnected ecosystems such as GST, Customs, and the Indian Council of Medical Research (ICMR). Transparent approval timelines will allow applicants to track progress in real time.

Digital Authentication to Strengthen Exports

A central feature of the DDRS is the integration of QR-code-based digital authentication for export documents, including Good Manufacturing Practice (GMP) certificates and Certificates of Pharmaceutical Product (CoPP). These certificates are necessary for Indian companies entering regulated foreign markets, where processing delays have historically presented logistical challenges.

By offering international regulatory agencies a reliable way to verify the compliance status of Indian medicines instantly, the system aims to clear non-tariff barriers and reinforce international trust in Indian pharmaceuticals. Expanding global acceptance of the Indian Pharmacopoeia—which is currently recognized by 24 countries—remains a strategic priority linked to this digital upgrade.

Official Roadmap and System Implementation

Dr. Rajeev Singh Raghuvanshi, Drugs Controller General of India (DCGI), outlined the 18-month deployment window during a recent address, calling the DDRS a critical step forward for the country’s drug regulatory infrastructure.

The initiative aligns with the Government of India’s broader Digital India agenda. It follows a Request for Proposal (RFP) published on the Government e-Marketplace (GeM) to select a technology software partner, setting the stage for a phased deployment over the next year and a half.

Industry Response: Encouraged, But Focused on Execution

Leaders across the pharmaceutical and medical device sectors have reacted positively to the planned update while noting that long-term success depends on technical execution and state-level coordination.

“Despite earlier digitalization efforts, the current framework still involves notable manual intervention. A well-executed DDRS could build a more integrated, transparent, and time-bound regulatory system—improving oversight while making it easier to do business.”

— Bhavin Mehta, Vice-Chairperson of Pharmexcil

Representatives from the medical technology sector also expressed support for the central vision.

“A single-window, paperless workflow with automated alerts, standardized data fields, and interoperability between state and central authorities is a step in the right direction. Industry is ready to collaborate on user testing and mapping specialized MedTech pathways to ensure the platform is effective and globally aligned.”

— Rajiv Nath, Forum Coordinator at AiMED

Context: Building on Earlier Digital Initiatives

The DDRS builds upon earlier digital initiatives introduced by the CDSCO, including:

1. The National Single Window System (NSWS): Aimed at simplifying business setup approvals.

2. The Online National Drug License System (ONDLS): Branded as the “One Nation-One Drug Licensing System” to harmonize state licenses.

3. Track and Trace Mechanisms: QR code requirements for active pharmaceutical ingredients (APIs) and top formulation brands to improve supply chain transparency.

While these tools helped establish early digital frameworks, uneven adoption and software bugs underscored the need for a unified end-to-end system.

Public Health and Clinical Implications

For patients and healthcare professionals, an efficient regulatory framework can help accelerate access to modern therapeutics, vaccines, and advanced medical devices. Streamlined approvals combined with real-time supply chain tracking can also support post-market surveillance, making it easier to identify and recall substandard products.

Technical Challenges and Operational Considerations

Despite the promising framework, implementation faces operational challenges. IT teams must execute smooth data migrations from legacy databases, onboard state drug controllers across regions, maintain cybersecurity standards, and ensure uptime.

Past issues with ONDLS implementation—where processing times occasionally stretched from an intended 45-day window to six months due to data mismatches and lack of visibility—highlight the importance of thorough testing before widespread deployment. Industry groups plan to submit recommendations to the CDSCO to help address operational friction during the transition.

Medical Disclaimer

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

1. CDSCO Announcement: “Digital Drug Regulation: CDSCO to Introduce Integrated Compliance Platform in 18 Months.” Medical Dialogues, July 2026.